Startup profile · funding coverage
Allotera Therapeutics funding, valuation and investors
Clinical-stage allogeneic (off-the-shelf) CAR-T company for T-cell malignancies — formerly Wugen.
Keep track of Allotera Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Equity financing (Series C–class)
$115M · August 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$115M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · St. Louis, MO
Investors in latest funding
Lead: Fidelity Management & Research Company
Other: RiverVest Venture Partners , Lightchain Capital , Abingworth , Tybourne Capital Management
Overview
Allotera Therapeutics (formerly Wugen) is a St. Louis clinical-stage biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for hematologic malignancies. Its lead program soficabtagene geleucel (WU-CART-007) is a CD7-targeted allogeneic CAR-T engineered with CRISPR gene edits to reduce fratricide and GvHD risk, manufactured from healthy donor T cells. In August 2025 the company announced a $115 million equity financing led by Fidelity Management & Research Company, with RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and others, to advance the pivotal T-RRex trial in relapsed/refractory T-ALL/T-LBL. Earlier Series B (2021) raised $172M led by Tybourne and Abingworth. Live site: alloteratx.com (wugen.com redirects).
Why Allotera Therapeutics is interesting
St. Louis clinical biotech (formerly Wugen) advancing off-the-shelf CD7 CAR-T; closed $115M financing (Aug 2025) led by Fidelity to fund the pivotal T-RRex study — WashU-rooted allogeneic cell therapy bet.
Product & use cases
Allogeneic CAR-T pipeline led by CD7-targeted sofi-cel for T-ALL/T-LBL, designed for off-the-shelf use from donor cells.
- Relapsed/refractory T-ALL treatment in pivotal trials
- T-cell lymphoblastic lymphoma investigational therapy
- Scalable off-the-shelf cell therapy manufacturing
Key facts
- Equity financing (Aug 2025): $115M led by Fidelity to advance pivotal T-RRex study (company / BioPharma Dive)
- Formerly Wugen; rebranded to Allotera Therapeutics (alloteratx.com)
- Lead asset: soficabtagene geleucel (WU-CART-007), allogeneic CD7 CAR-T
- Prior Series B (2021): $172M led by Tybourne/Abingworth per coverage
Funding history (newest first)
Equity financing (Series C–class)
2025-08 $115M- Fidelity Management & Research Company (lead)
- RiverVest Venture Partners (participant)
- Lightchain Capital (participant)
- Abingworth (participant)
- Tybourne Capital Management (participant)
Competitive landscape
Edge: Allogeneic CD7 CAR-T aimed at T-cell cancers where autologous CAR-T is hard — St. Louis clinical biotech with large 2025 financing.
-
Autologous CAR-T (Kymriah/Yescarta-class) incumbent
Patient-specific CAR-T manufacturing.
-
Other allogeneic CAR-T developers direct
Off-the-shelf cell therapy peers.
-
Bispecifics / other T-cell engagers adjacent
Alternative modalities in hematologic oncology.
Notable stories
- Company materials describe WashU/St. Louis roots for the allogeneic CAR-T platform; wugen.com redirects to Allotera branding.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Allotera Therapeutics's financing or category context.
FAQs about Allotera Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.